Search

Al Roker, anchor of NBC’s TODAY, shared an update on his successful treatment for prostate cancer at MSK in a recent segment on the broadcast. 

… Tuesday, November 17, 2020 Al Roker, anchor of NBC’s TODAY , shared an update on his successful treatment for prostate cancer at Memorial Sloan Kettering (MSK) in a recent segment on the broadcast . Al had previously announced his diagnosis on the show prior to having surgery for the disease. “Al’s surgery

An international group of investigators led by scientists at Memorial Sloan Kettering Cancer Center and the National Cancer Institute has identified a new genetic marker of risk for breast cancer. Women with this DNA variation are at a 1.4 times greater risk of developing breast cancer compared to those without the variation.

… Monday, March 3, 2008 An international group of investigators led by scientists at Memorial Sloan Kettering Cancer Center (MSKCC) and the National Cancer Institute has identified a new genetic marker of risk for breast cancer . Women with this DNA variation are at a 1.4 times greater risk of developing

Learn about the different types of benign breast lumps.

… Friday, May 24, 2024 What should you do if you notice a lump in your breast? Don’t panic. See your doctor. “Many lumps turn out to be benign,” says Memorial Sloan Kettering Cancer Center breast radiologist Kimberly N. Feigin, MD , Acting Chief of Breast Radiology at MSK. “But the most important thing

New data from a study led by Memorial Sloan Kettering physicians that used targeted therapy for patients with the most common type of lung cancer has helped transform treatment for the disease.

… Tuesday, May 20, 2014 Data Supports Routine Tumor Genotyping for Patients with Advanced Lung Cancers; May Improve Survival New data from a study led by Memorial Sloan Kettering physicians that used targeted therapy for patients with the most common type of lung cancer has helped transform treatment for

Immunotherapy pioneers Michel Sadelain, MD, PhD, of Memorial Sloan Kettering Cancer Center (MSK), and Carl June, MD, of the University of Pennsylvania, have published a seminal review of the current landscape of chimeric antigen receptor (CAR) therapy in the New England Journal of Medicine (NEJM). In the comprehensive review article, Drs. Sadelain and June highlight the emerging immunotherapy treatment for hematologic cancers known as CAR T cells, which was developed at MSK. The paper is the first in a series being published by NEJM. Known as Frontiers in Medicine, it will showcase ways that new technologies are influencing contemporary medicine and science.

… Wednesday, July 4, 2018 Immunotherapy pioneers Michel Sadelain, MD, PhD, of Memorial Sloan Kettering Cancer Center (MSK), and Carl June, MD, of the University of Pennsylvania, have published a seminal review of the current landscape of chimeric antigen receptor (CAR) therapy in the New England Journal

Learn how multiple myeloma prognosis has improved significantly with the emergence of new drug treatments.

… Tuesday, January 27, 2026 Note: This story was originally published in 2022 and has been updated. Saad Usmani, MD , a hematologic oncologist specializing in multiple myeloma , is Chief of the Myeloma Service at Memorial Sloan Kettering Cancer Center (MSK). Dr. Usmani has more than 15 years of experience

Gerstner Sloan Kettering held its inaugural retreat, on April 30 and May 1, to foster scientific and personal exchanges between students and faculty.

… Saturday, May 15, 2010 Gerstner Sloan Kettering held its inaugural retreat, on April 30 and May 1, to foster scientific and personal exchanges between students and faculty. The retreat brought together 32 students and 28 faculty members, as well as school leadership and keynote speakers for two days

Researchers found that Black race was the strongest predictor of lymphedema development with a 3.5-fold increased incidence of lymphedema in Black women compared to White women.

… Tuesday, December 7, 2021 New data from researchers at Memorial Sloan Kettering Cancer Center (MSK) featured in the 2021 San Antonio Breast Cancer Symposium (SABCS) press program highlights the important impact that race and ethnicity have on the incidence and severity of breast cancer–related lymphedema

The tool will aid basic and translational researchers interested in understanding why immune cells stop working.

… Friday, April 23, 2021 Our immune system is great at protecting us from infections and cancer. Except when it doesn’t. For reasons that are not entirely clear, the T cells that normally mount an effective response against infections and cancer sometimes find themselves unable to vanquish these foes and

New MSK research reports encouraging results for a new liposarcoma treatment; describes more potent CAR T cells that can be given at lower doses; relates a new way of making drug-delivery nanoparticles more efficient; identifies CAR T cells that activate at the tumor site; and sheds light on how — in very rare cases — a CAR T cell treatment might lead to a new cancer arising.

… Thursday, February 6, 2025 New research from Memorial Sloan Kettering Cancer Center (MSK) reports encouraging results for a new liposarcoma treatment; describes more potent CAR T cells that can be given at lower doses; relates a new way of making drug-delivery nanoparticles more efficient; identifies